Market Signal Briefing

Nuclear energy continues to dominate the headlines, and Centrus Energy is one company that could help the U.S. secure domestic production.

Shares of Centrus Energy (LEU -1.87%) increased 53.7% in September, according to data provided by S&P Global Market Intelligence.

Centrus Energy, a leading U.S. supplier of nuclear fuel and enrichment services, benefited from news that the U.S. government is supporting policies aimed at boosting domestic production of nuclear materials. The company also announced it would expand its U.S.-based enrichment plant to support U.S. production and reduce reliance on foreign entities. Here's what investors need to know.

Image source: Getty Images.

Centrus Energy's leap comes amid growing support for U.S. nuclear production
On Sept. 15, U.S. President Donald Trump's administration announced that it would take steps to support domestic nuclear materials production and enrichment.

U.S. Energy Secretary Chris Wright recommended that the U.S. increase its strategic uranium reserve to help buffer against Russian supplies. Russian supplies were banned in August 2024. This ban won't be fully phased in until 2028, when waivers allowing limited Russian deliveries expire. This creates a significant need to replace approximately 25% of enriched uranium currently imported from Russia.

The recommendation to boost the uranium reserve boosted confidence across the industry, driving several uranium and nuclear stocks higher during the month.

Increased support from the federal government is a positive development for Centrus, which plans a major expansion to boost production of Low-Enriched Uranium (LEU) and High-Assay, Low-Enriched Uranium (HALEU). Centrus currently has two commercial agreements to sell LEU, one of which is with TEXEX, a Russian entity.

In the long term, Centrus aims to produce LEU and HALEU at its Piketon, Ohio plant, utilizing its advanced centrifuge technology. It is the only Nuclear Regulatory Commission (NRC) licensed producer of HALEU currently operating at scale for both commercial and national security applications.

The expansion of its Ohio plant hinges on Department of Energy funding, private investment, and long-term customer commitments. Centrus has raised over $1.2 billion and secured contingent purchase commitments of $2 billion from utilities. However, the full scale and timing of the expansion remain contingent on federal funding decisions from the Department of Energy.

With the U.S. signaling a willingness to support domestic production of key mineral resources, this is a good sign that Centrus could secure the necessary funding to expand its operations and become a top domestic supplier of LEU and HALEU uranium. While HALEU is not currently used in commercial reactors, it is essential for advanced reactor designs under development, making it critical for next-generation nuclear technology.

Centrus is well-positioned for a nuclear revival
Centrus Energy is riding the wave higher as uranium and nuclear power-related stocks surge. This demand is likely to persist, too, given the massive amount of energy required to power the data centers behind artificial intelligence (AI).

The company's Piketon facility has the potential to be crucial to domestic fuel production. However, scaling it will require time and capital and hinges on securing funding. The stock trades at a premium today, but for investors who believe in the long-term nuclear revival, Centrus is one way to gain exposure to it.

Courtney Carlsen has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fly-E Group, Inc. (NASDAQ: FLYE) between July 15, 2025 and August 14, 2025, both dates inclusive (the “Class Period”), of the important November 10, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Fly-E securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Fly-E class action, go to https://rosenlegal.com/submit-form/?case_id=44575 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 10, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the safety of Fly-E’s lithium battery which in turn took a material toll on its E-vehicle sales revenue, despite making lofty long-term projections, Fly-E’s forecasting processes fell short as sales continued to decline and operating expenses increased, ultimately, derailing Fly-E’s revenue projections. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Fly-E class action, go to https://rosenlegal.com/submit-form/?case_id=44575 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Centrus Energy has skyrocketed over 300% on the year -- is it an obvious buy for growth?

Centrus Energy (LEU -1.60%) offers investors something rare: A pure play on the supply side of U.S. nuclear power.

As one of two U.S. suppliers licensed to produce low-enriched uranium (LEU), and one of one to produce high-assay low-enriched uranium (HALEU), the nuclear energy stock appears ideally positioned to profit from Washington's push to obtain nuclear independence.

At the time of writing, Centrus stock is up an eye-watering 323% on the year and over 470% year over year. But whether this is a no-brainer growth stock depends on how well this company executes on its promises and how long favorable policy winds continue in its sails.

Image source: Getty Images.

What exactly does Centrus do?
Centrus, at its core, is a nuclear fuel supplier. Simply put, it provides LEU -- the standard fuel used in today's nuclear reactors -- through long-term purchase agreements.

Centrus' enrichment capacity is small but growing. In late 2023, it fired up operations at the American Centrifuge Plant in Piketon, Ohio, the first U.S.-owned enrichment plant to start production since 1954.

That same plant is currently the only U.S. facility licensed to produce HALEU, a special kind of nuclear fuel that's needed for next-generation reactors.

Until recently, production of HALEU on a commercial scale was done outside the U.S. (think: Russia). But with the Biden administration's former push for emission-free power, and the Trump administration's push for national security, production of HALEU on U.S. soil has become an urgent matter.

On that note, Centrus has a contract with the U.S. Department of Energy (DOE) to produce high-assay low-enriched uranium (HALEU). In mid-June, it delivered 900 kilograms of HALEU to the DOE, the second delivery of that fuel in two years. It's now entered phase III, which calls for another 900 kilograms of HALEU through June 30, 2026.

A growth story that may have already hit its climax
Like other nuclear energy stocks, Centrus comes with an asterisk. And that asterisk is its valuation.

Between mid-2024 and mid-2025, Centrus' market cap ballooned from about $684 million to more than $5.5 billion, an eightfold increase driven mostly by policy tailwinds and its delivery of HALEU to the DOE. In the same period, Centrus' net income decreased slightly from $30.6 million to $28.9 million even as gross profit increased to $53.9 million from $36.5 million.

LEU data by YCharts.

I'm OK with Centrus' financial situation, as it has a solid balance sheet and positive cash flow. The kicker, however, is how other valuation metrics have exploded with today's $5.5 billion market cap.

At today's price, the stock trades almost 50 times trailing earnings and 77 times forward earnings. This points to an expectation of explosive near-term growth. With Centrus operating only one enrichment facility right now -- and at a limited production capacity at that -- it could take a half decade before revenue growth catches up to these numbers.

Centrus' growth also depends in part on the rollout of next-generation nuclear reactors, several of which are designed to run on HALEU. Many of these designs are still in development -- many don't even have regulatory approval yet -- and could take a few years before they move from blueprint to commercial plant.

That's not to suggest that Centrus isn't going to be a key player in a future market of HALEU fuel. But this market is still very much more future than present. A lot can happen between now and then, like a new administration, for instance, with a different energy agenda.

Because of that, Centrus is not a no-brainer for growth. It's a speculative play that requires thought and planning. For growth investors who can stomach the risk, the long-term payoff could be worth the volatility. Otherwise, a nuclear energy exchange-traded fund (ETF) could be a less risky venture.

Steven Porrello has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Fortinet, Inc. (NASDAQ: FTNT) between November 8, 2024 and August 6, 2025, both dates inclusive (the "Class Period"), of the important November 21, 2025 lead plaintiff deadline.

So what: If you purchased Fortinet common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Fortinet class action, go to https://rosenlegal.com/submit-form/?case_id=45210 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 21, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants made materially false and misleading statements concerning the business impact and sustainability of a purportedly "record" round of FortiGate unit upgrades. Defendants represented that this "refresh cycle" was "by far the largest we've seen probably ever," would generate "around $400 million to $450 million in product revenue" in 2025 and 2026, and would create strong opportunities to cross-sell additional products and services. Defendants also represented that the refresh cycle would "gain momentum" in the second half of 2025 and beyond.

The lawsuit alleges these statements were materially false and misleading. In truth, defendants knew that the refresh cycle would never be as lucrative as they represented because it consisted of old products that were a "small percentage" of the Company's business. Moreover, defendants misrepresented and concealed that they did not have a clear picture of the true number of FortiGate firewalls that could be upgraded. And while telling investors that the refresh would gain momentum over the course of two years, Fortinet misrepresented and concealed that it had aggressively pushed through roughly half of the refresh in a period of just a few months, by the end of 2Q 2025. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Fortinet class action, go to https://rosenlegal.com/submit-form/?case_id=45210 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Legendary billionaire investor Bill Nygren and his team over at the Oakmark Select fund made quite a few notable moves in the second quarter.

Weekly Light Crude Oil Futures
Last week’s bearish close below the 52-week moving average at $63.08 and the long-term pivot at $64.21 confirmed a shift in trend structure. The technical breakdown sets up a potential test of major Fibonacci support at $59.91. A weekly close beneath that level could expose the May 2024 low of $55.74 as the next downside target.

With long-term indicators now pointing lower, the weekly chart reflects a clear deterioration in bullish control.

Demand Signals Weaken as Shutdown Threat Weighs on U.S. Consumption
U.S. consumption risks added further pressure to the complex. The government shutdown has frozen key data releases from the Bureau of Labor Statistics, creating a policy blind spot for the Federal Reserve ahead of its late October meeting.

More immediately, the furlough of up to 750,000 federal workers threatens to dent household spending—especially in energy-sensitive sectors like travel, autos, and appliances. Softer demand trends are already surfacing in the Atlantic Basin, where seasonal refinery turnarounds are reducing crude runs.

Bearish Market Outlook: WTI Risks Retest of May Lows
With WTI crude trading below its 52-week average and long-term pivot, the path of least resistance remains lower. Unless prices reclaim $63.08 on a weekly close, the technical setup favors further downside toward $59.91 and potentially $55.74. The crude oil prices forecast remains bearish for the week ahead.

Tom Yeung here with your Sunday Digest. 

In 1792, 24 merchants and brokers gathered on Wall Street to sign the Buttonwood Agreement, which became the foundation for the New York Stock Exchange (NYSE).  

They got a great deal. 

Over the following two centuries, entry into the fast-growing NYSE became harder and pricier to come by. By the 1990s, memberships (seats) were sold for over $6 million in inflation-adjusted dollars. 

Now, the funny thing about these types of security “marketplaces” is that they are the ultimate network effect business. The more people on an exchange, the more trading that happens. That brings more action-seeking traders on board, which builds more liquidity, and so on.  

Imagine trying to sell a rare baseball card on the secondhand market. The more people in that marketplace, the better the chance of selling the card for a great price. 

Securities trading puts this in overdrive, since even a “small” institutional order might involve selling millions of shares to thousands of different buyers. An average retail investor might move hundreds of shares at a time. 

That’s why exchange-type marketplaces are so incredibly valuable. Germany’s Deutsche Boerse (DBOEY), for instance, is the eleventh-largest stock on its own exchange. Hong Kong’s is its ninth, while Singapore’s is its sixth. The tiny margins these exchanges take from trades quickly add up. 

Even better, some exchanges occasionally find a special sauce… a tradable asset that is either so new that no one else is trading it… or a proprietary one that only the exchange itself is allowed to move. 

This might sound like a total racket. And sometimes it is. But it’s how many monopolistic exchanges turn ordinary trading activities into billion-dollar businesses. 

Over the past year, you’ve seen me recommend several of these high-performing firms here in your Sunday Digest. On average, these picks have risen 23%, beating the S&P 500 more than twice over. Two of these are so conservative that the “Liberation Day” selloff barely registered on their stock prices. 

In today’s Digest, I’d like to revisit my three recommendations, which highlight why it’s so important to get in early on these deals. I’ll also note why they’re still compelling trades.  

The Futures King 
The mid-1800s saw the completion of canal and railroad infrastructure around Chicago. For the first time, traders could move products between the Great Lakes and the Mississippi River without using horse-drawn wagons. 

To handle this commerce, a group of merchants formed the Chicago Board of Trade. The exchange quickly became a central marketplace for grain, and a separate Chicago Mercantile Exchange was soon established to handle butter and eggs. To ensure product quality, each keg of butter was individually tasted – a job that surely had no shortage of applicants. Surplus butter was salted and stored in the basement for future sale… hence the establishment of “futures contracts.” 

Today, these exchanges live on as the CME Group Inc. (CME), a global leader in futures trading. The Chicago-based exchange dominates certain types of futures contracts, including U.S. interest rate futures (over 95% market share), and issues 100% of all futures contracts on the S&P 500, Russell 2000, and Nasdaq indexes, where it has an exclusive license. It also remains a major player in agricultural futures… even though its butter tasters are now long gone. 

That’s why I added this financial exchange to my list of top cyclical stocks to buy for 2025. Firms like CME thrive on volatility, and an unwarranted selloff in December 2024 created a perfect time to buy.  

Since then, CME shares rose as much as 25% before settling at a 14% gain as of this week. 

The recent selloff now provides a second opportunity to buy into a company that typically rises during periods of high volatility. 2007, 2019, and 2022 were banner years for CME, and shares will likely recover as traders cover their bets in the face of uncertain markets. 

The Options Queen 
In 1973, the Chicago Board of Trade created a separate exchange to list stock options. 

Few people liked the idea at the time. Officials at the Securities and Exchange Commission compared options to gambling, advising, “Don’t waste another nickel on it.” Even the Chicago Board of Trade didn’t take the expansion project seriously at first; they crammed their new options exchange into a former smoking lounge next to its vast commodity trading floor. 

But Cboe Global Markets Inc. (CBOE) surprised skeptics. Over the following years, options became a dominant force in risk management, pulling Cboe up along with it. Today, the firm maintains proprietary ownership over options on the S&P 500 and the Cboe Volatility Index (VIX). As a result, the Chicago-based spinoff has a 99% market share in index options. 

That’s helped Cboe notch a 24% return since I also added it to my list of top cyclical stocks to buy for 2025. The firm has reported accelerating revenue growth (from 5% in the fourth quarter of 2024 to 14% in the most recent quarter), and rising volatility should continue pushing shares higher in the medium term.  

In addition, zero-day-to-expiry (0DTE) options have become wildly popular among retail traders. Volumes of 0DTE options have risen fivefold over the past three years, boosting revenues at Cboe to even-higher records. 

That’s why analysts expect Cboe to report a 13% increase in earnings per share this year, and for that figure to keep rising at 7% for the foreseeable future. Though options are now a relatively mature industry, Cboe has managed to keep an iron grip on some of the world’s most traded options. 

The Day Trading “Prince” 
Finally, there’s Robinhood Markets Inc. (HOOD), a firm that took quick advantage of the meme stock rally of 2020 to hook a new generation on trading. I recommended shares in June after one of our top AI systems flagged the stock right as interest in day trading was bouncing back. Robinhood has traditionally benefited from this lucrative business. 

Since then, shares of Robinhood have risen 30%. 

The company is now encountering a new opportunity in prediction markets – an industry that only recently became legal in America. Prediction market trading has become incredibly popular among younger traders, and Robinhood has moved aggressively to expand its market share before anyone else. Remember, exchanges have phenomenal first-mover advantages since traders gravitate towards the marketplace with the highest liquidity, creating a virtuous cycle. 

That could create an unexpected boom for Robinhood’s business. Some analysts believe prediction market betting will grow 28% annually through 2030, and this potential $80 billion market isn’t yet reflected in Robinhood’s share price. 

In addition, prediction markets offer opportunities for institutional investors and companies to reduce risk, which could help Robinhood expand its customer base. For example, a government contractor at risk of getting furloughed can bet on a federal government shutdown on November 21. If the government stays open, the contractor gets paid by the government. And if not, the prediction markets pay out. Either way, the contractor can make payroll that month. 

Now, it’s important to note that Robinhood remains far riskier than CME or CBOE. The newer exchange has a history of aggressive marketing; it has paid millions in fines to FINRA and the SEC as a result. However, Robinhood now finds itself in a perfect position to dominate an entirely new market. Rival exchange Polymarket remains off-limits to American citizens. Kalshi, a separate prediction market, is still relatively unknown among traders. It won’t be a cakewalk for Robinhood, either. But the potential payoffs from success are vast. 

The $4 Trillion Opportunity Hiding in Plain Sight 
Most folks are aware of prediction markets. Analysts use them to establish baseline probabilities, while gamblers might even use it to pick out a fantasy sports team. It’s only a matter of time before they open an account and make trades directly. 

Now, InvestorPlace Senior Analyst Luke Lango believes he’s found something even more compelling… a $4 trillion trading market so new that few exchanges have yet figured out how it works. 

But Luke has.  

He sees an incredible opportunity brewing – and it’s all thanks to President Donald Trump’s Executive Order 14178. So, tomorrow, at 1 p.m. Eastern, Luke will be hosting a groundbreaking broadcast called President Trump’s “Project Yorktown” Summit to discuss this order and the financial revolution it’s set to unleash on global financial markets. He will also cover the exchanges trading these new assets, and how they are unlike anything the financial world has seen before.  

You’ll also learn how positioning yourself now could lead to 10X gains in 12 months… 30X gains in three years… and even potentially 100X gains by 2030. 

Plus, Luke will give away a free stock pick poised to double within 12 months. 

Click here to sign up now. 

Until next week, 

Thomas Yeung, CFA 

Market Analyst, InvestorPlace 

Thomas Yeung is a market analyst and portfolio manager of the Omnia Portfolio, the highest-tier subscription at InvestorPlace. He is the former editor of Tom Yeung’s Profit & Protection, a free e-letter about investing to profit in good times and protecting gains during the bad.

The so-called debasement trade — embraced by individual investors since late 2024 as a hedge to a weaker dollar — could accelerate from here.

NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (“Unicycive” or “the Company”) (NASDAQ: UNCY) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Unicycive securities between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/UNCY.

Case Details

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1)Unicycive's readiness and ability to satisfy the FDA's manufacturing compliance requirements was overstated; (2) the OLC NDA's regulatory prospects were likewise overstated; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/UNCY. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Unicycive you have until October 14, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]

NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against SelectQuote, Inc. (“SelectQuote” or “the Company”) (NYSE: SLQT) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired SelectQuote securities between September 9, 2020 and May 1, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/SLQT.

Case Details

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that the Company was directing Medicare beneficiaries to the plans offered by insurers that best compensated SelectQuote, regardless of the quality or suitability of the insurers' plans; (2) that SelectQuote did not provide unbiased comparison shopping for Medicare Advantage insurance plans; (3) that SelectQuote received illegal kickbacks to steer Medicare beneficiaries to certain insurers and limit enrollment in competitors' plans; (4) that as a result, SelectQuote had not complied with applicable laws, regulations, and contractual provisions; (5) that SelectQuote was vulnerable to regulatory and legal sanctions as a result of its conduct, including claims that it had violated the False Claims Act; and (6) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On this news, SelectQuote's stock price fell $0.61, or 19.2%, to close at $2.56 per share on May 1, 2025, on unusually heavy trading volume.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/SLQT. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in SelectQuote you have until October 10, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]

NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Quanex Building Products Corporation (NYSE: NX) between December 12, 2024 and September 5, 2025, both dates inclusive (the “Class Period”), of the important November 18, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Quanex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Quanex class action, go to https://rosenlegal.com/submit-form/?case_id=45157 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 18, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Quanex’s procedures and policies regarding tooling and equipment maintenance in its Tyman Mexico facility were significantly “underinvested”; (2) as a result, Quanex’s tooling and equipment conditions had significantly degraded to near “catastrophic” levels; (3) as a result of the foregoing, Quanex was likely to incur significant costs, “pushing out the timing” of expected benefits from the Tyman integration; (4) Quanex had previously identified the foregoing issues; and (5) as a result of the foregoing, defendants’ positive statements about Quanex’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Quanex class action, go to https://rosenlegal.com/submit-form/?case_id=45157 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Semler Scientific, Inc. (NASDAQ: SMLR) between March 10, 2021 and April 15, 2025, both dates inclusive (the “Class Period”), of the important October 28, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased Semler Scientific securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Semler Scientific class action, go to https://rosenlegal.com/submit-form/?case_id=39889 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 28, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Semler Scientific did not disclose a material investigation by the United States Department of Justice (the "DOJ") into violations of the False Claims Act, while discussing possible violations of the False Claims Act (and aggressive DOJ enforcement thereof) in hypothetical terms; and (2) as a result, defendants' public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Semler Scientific class action, go to https://rosenlegal.com/submit-form/?case_id=39889 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Its new retail voting program is no ‘power grab.'

Gold price extends 7-week rally as the Fed faces a data blackout and shutdown risks fuel $4000 forecasts. Traders brace for a key week in gold analysis.

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led to a pooled 16.4% (p

SummaryI am upgrading Chipotle to a “buy” with a $52 price target per share, implying 26% upside from current levels.Chipotle’s Q2 FY25 results were disappointing, but management’s focus on technology, menu innovation, and loyalty programs is expected to drive growth from Q3 onward.Plus, Chipotle has been improving its profitability driven by cost controls and menu pricing, with revenue and earnings growth expected to accelerate through FY27.I believe that there is room for multiple expansions, as acceleration in both its top and bottom lines from Q3 onwards could lead to a potential stock rerating.sanfel/iStock Editorial via Getty Images

Introduction & Investment Thesis When I last wrote about Chipotle (CMG), I reiterated my "hold" rating, as I believed the pain was not over yet. In the post, I discussed that the company would face tougher comps for

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in CMG over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- MAGACOIN FINANCE, an Ethereum-based cryptocurrency project, today announced it has raised over $15.5 million in its ongoing presale with more than 14 000 global investors.

The milestone arrives amid growing Bitcoin ETF anticipation, which is driving renewed interest in Ethereum-built altcoins showing measurable traction.

Presale Highlights

Funds raised: $15.5 million +
Investors: 14 000 + participants
Allocation sold: ≈ 80 % complete
Launch price: $0.007 per token The project’s stage-based model raises token prices incrementally as supply shrinks, creating a built-in scarcity mechanism for early participants.

Bitcoin ETF Momentum and Altcoin Shift

With market focus centered on pending Bitcoin ETF developments, analysts report a spillover of capital toward lower-cap Ethereum projects like MAGACOIN FINANCE. The project’s $15.5 M achievement places it among the cycle’s most funded early-stage entries.

Why Investors Are Watching

Measured funding milestone of $15.5 M.
Large and growing global community.
Ethereum-based architecture aligned with institutional trends

Conclusion

As ETF buzz builds around Bitcoin and flows extend to altcoins, MAGACOIN FINANCE’s fundraising progress highlights the market’s renewed appetite for Ethereum-based projects with clear tokenomics and presale momentum.

About MAGACOIN FINANCE

MAGACOIN FINANCE is an Ethereum-based cryptocurrency project combining cultural relevance with scalable blockchain utility. With over $15.5 million raised and a rapidly growing community, it aims to be a leading altcoin entrant of 2025.

Learn more:

Website: https://magacoinfinance.com
Access: https://magacoinfinance.com/access
Twitter/X: https://x.com/magacoinfinance
Telegram: https://t.me/magacoinfinance

Contact Details

PR Specialist: Rebecca Miles
Email: [email protected]

Disclaimer: This content is provided by MAGACOIN FINANCE. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading advice. Investing in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector--including cryptocurrency, NFTs, and mining--complete accuracy cannot always be guaranteed. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page.

Legal Disclaimer: This media platform provides the content of this article on an "as-is" basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above.

Photos accompanying this announcement are available at 

https://www.globenewswire.com/NewsRoom/AttachmentNg/28c20655-503f-4a9b-87f7-265bdbb32da2

https://www.globenewswire.com/NewsRoom/AttachmentNg/01040c99-688e-41ce-ba87-98a380eb6a2b

https://www.globenewswire.com/NewsRoom/AttachmentNg/4a13f696-ad93-40b5-a903-f6ec8c8ceb54

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

October 05, 2025 09:00 ET

 | Source:

Spyre Therapeutics, Inc.

WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced scientific presentations at the UEGW Congress.

“We are excited to share follow-up data out to six months from our Phase 1 study of SPY002, our potential best-in-class anti-TL1A agent in development for IBD. The data continue to show SPY002 is well tolerated, has a differentiated PK profile supporting quarterly or twice-yearly dosing, and suppresses free TL1A through 24 weeks,” said Josh Friedman, M.D., Ph.D., SVP of Clinical Development at Spyre. “Additionally, we are pleased to share new preclinical data demonstrating that each of our combination programs (α4β7 + TL1A, α4β7 + IL-23, and TL1A + IL-23) exhibit superior efficacy relative to constituent monotherapies in rodent TNBS-induced colitis models, providing additional validation for our ongoing SKYLINE-UC Phase 2 study.”

The poster will be available for viewing during the UEGW Congress, and details are as follows:

Title: Interim Phase 1 Results for SPY002, a Novel Half-Life Extended Monoclonal Antibody Targeting TL1A, Suggests a Potential for Q3M or Q6M Maintenance Dosing for Inflammatory Bowel Disease
Authors: Y. Vugmeyster, S. Sloan, JD Lu, K. Hew, P. Patel, C. Sheldon, D. Nguyen, R. McLean, M. Huyghe, B. Connolly, B. Wang, M. Kennedy, M. Rose, E. Svejnoha, J. Friedman

Title: Combined Inhibition of Integrin β7 and TL1A, Integrin β7 and IL-23, or TL1A and IL-23 Are Superior to Their Constituent Monotherapies in Mouse TNBS-Induced Colitis
Authors: M. Siegel, J. Friedman, E. Lewis, D. Giles, A. Spencer

Full session details can be accessed via the UEGW program.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

For more information, please visit http://spyre.com. 

Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, concerning Spyre and other matters. These forward-looking statements include, but are not limited to, express or implied statements relating to Spyre's management team's expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, Spyre’s ability to achieve the expected benefits or opportunities with respect to its pipeline of product candidates such as the potential efficacy, tolerability, convenience, commercial viability, dosing regimen and safety profile of SPY002 in humans, including the potential for a quarterly or twice yearly dosing profile; the potential for SPY002 to become a best-in-class therapy for IBD; the potential consistency of the SPY002 Phase 2 trial final data readouts with interim Phase 1 results; and the potential therapeutic benefits of Spyre’s product candidates as monotherapies or in combinations and their extended half-life, including the expected duration of half-life in comparison to competitor products and the potential potency, efficacy and convenience compared to today’s standard of care. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "opportunity," "potential," "milestones," "pipeline," "can," "goal," "aim," "strategy," "target," "seek," "anticipate," "achieve," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "predict," "project," "should," "will," "would," and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Spyre will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Spyre's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited, uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with the Company’s interpretation of data and the Company’s clinical trials for its product candidates, including our plans for and timing of cohort initiation for combination therapy arms for the ongoing SKYLINE-UC Phase 2 platform trial across different jurisdictions; the potential for final data not being consistent with or different than the interim data reported for our programs; the potential impact of Trump Administration policies and changes in law on our business; and those uncertainties and factors described under the heading "Risk Factors," "Risk Factor Summary" and "Note about Forward-Looking Statements" in Spyre's most recent Annual Report on Form 10-K, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that the Company has filed or will file with the SEC, as well as discussions of potential risks, uncertainties, and other important factors included in other filings by Spyre from time to time. Should one or more of these risks or uncertainties materialize, or should any of Spyre's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Spyre does not undertake or accept any duty to make any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in Spyre.

For Investors:     
Eric McIntyre
VP of Finance and Investor Relations
Spyre Therapeutics
[email protected] 

For Media:     
Josie Butler, 1AB
[email protected] 

, /PRNewswire/ -- Berger Montague PC, national plaintiffs' law firm, announces a class action lawsuit against LifeMD, Inc.  (NASDAQ: LFMD) ("LifeMD" or the "Company") on behalf of investors who purchased or acquired shares during the period from May 7, 2025 through August 5, 2025 (the "Class Period").

Investor Deadline: Investors who purchased or acquired LifeMD securities during the Class Period may, no later than October 27, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE .

LifeMD, headquartered in New York, New York, is a telehealth provider offering direct-to-patient virtual care and pharmacy services.

According to the suit, LifeMD issued materially false and/or misleading statements regarding its business and financial outlook. Specifically, the Company is accused of overstating its competitive position and raising its 2025 guidance without adequately accounting for escalating customer acquisition costs—particularly within its RexMD segment and for obesity-related drugs like Wegovy and Zepbound.

When the true facts were revealed, LifeMD shares fell 44%, or $5.31 per share, in a single trading session.

If you are a LifeMD investor and would like to learn more about this action, CLICK HERE  or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267)764-4865.

About Berger Montague
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

For more information or to discuss your rights, please contact:

Andrew Abramowitz
Senior Counsel
Berger Montague
(215) 875-3015
[email protected]

Caitlin Adorni
Director of Portfolio and Institutional Client Monitoring Services
Berger Montague
(267) 764-4865
[email protected] 

SOURCE Berger Montague

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Pfizer's stock has been struggling for multiple years, and even a low valuation hasn't made it an enticing option for many investors.

Pfizer (PFE 1.03%) is one of the largest healthcare companies in the world. It was founded in 1849 and has since become an iconic name in healthcare.

It has developed many medicines over the years; most recently, it has been known for developing its highly successful COVID vaccine Comirnaty. Growth and innovation have enabled the company to become a household name and a leader in healthcare.

Investors, however, have been having doubts about the business and its ability to grow in the future. In the past three years, the stock has produced negative returns. Since 2022, It has lost more than half its value. Can the stock break its downward streak, and finish this year in positive territory?

Image source: Getty Images.

A recent deal with the White House gives investors hope
For a while, it looked like Pfizer's stock was destined for another year in the red. The U.S. government has been targeting pharma companies with tariffs this year, and tougher vaccine policies have also been weighing on the company's valuation.

But on Sept. 30, Pfizer reached a deal with President Donald Trump that will give it a grace period of three years before tariffs would be applied to its imported pharmaceutical products. The company is voluntarily lowering the price of drugs for Medicaid and will sell some drugs on TrumpRx, a new government-run direct-to-consumer website for pharmaceuticals. In addition, the company also pledged to invest $70 billion on research and manufacturing in the U.S. over the coming years.

This appeared to alleviate at least some concerns for investors because shares of Pfizer jumped on the recent news. On Oct. 1, it closed above $27 for the first time since January. The stock is now in positive territory for 2025, with year-to-date gains around 3%. It's not a huge return, but it is an indication that investors are feeling a bit more bullish about the healthcare stock again and that it might be able to finish the year in the green.

Pfizer still faces a lot of questions
Although the stock has been rallying recently, it's not out of the woods by any means. COVID sales are diminishing for Pfizer, and the company is facing patent cliffs on multiple key drugs.

CEO Albert Bourla has previously said the company could stand to lose between $16 billion and $18 billion in revenue between 2025 and 2030 as it loses patent protection on some of its drugs. However, he's also planning to add $25 billion in new revenue by the end of the decade through acquisitions and research and development.

Its acquisition of oncology company Seagen could generate up to $10 billion in sales by 2030 alone. It was also expecting that its mRNA vaccine portfolio might bring in a similar amount, but that is questionable now that the U.S. government appears to be rethinking vaccine recommendations.

The business may end up looking a whole lot different over the next five-plus years. While its fundamentals still look good (it generated nearly $11 billion in profits over the trailing 12 months), investors are hesitant about whether or not they can trust this struggling stock, especially amid such uncertain times in the healthcare sector.

Why Pfizer may be worth taking a chance on
There's definitely risk with investing in Pfizer as it's taking on multiple acquisitions and facing patent cliffs, and there are plenty of question marks around its vaccine sales. However, with a beaten-down valuation, a price-to-earnings multiple of less than 13, and a price-to-earnings-growth ratio right around 1 (based on analyst projections), it's a low-priced stock that comes with a good margin of safety.

Pfizer has been working on expanding its pipeline and giving itself more opportunities to grow in the long run. Although not all of its efforts might pay off, even if some do, there could be plenty of catalysts in the future to send the stock higher.

Whether it breaks its streak of declines this year is irrelevant because investing in a quality company at a cheap price could ensure your investment ends up in the green over the long haul, and that's why Pfizer looks like a solid buy, regardless of what happens in the short term.

David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.

SummaryToyota remains the world's largest automaker, boasting strong global sales and industry-leading profitability despite recent tariff headwinds.TM's strategic decision to limit price hikes, leverage U.S. manufacturing, and absorb tariff costs is fueling sales growth while competitors raise prices.With a forward P/E of 10.77 and robust revenue growth, TM is undervalued and offers a low-risk, long-term opportunity.Toyota's reliable brand, operational excellence, and prudent strategy make TM a compelling buy-and-hold stock, well-positioned to outperform in a competitive industry.Zigmunds Dizgalvis/iStock Editorial via Getty Images

Toyota (NYSE:TM)(OTCPK:TOYOF) needs no introduction. The Japanese auto giant has been the largest car manufacturer in the world by volume for several years running. It sold more than 10 million

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

The share price of American technology giant Oracle (NASDAQ: ORCL) is looking to extend its recent momentum, with technical indicators pointing toward a potential move to the $1,000 level.

Notably, Oracle stock ended the last session trading at $286, having gained about 125% in the past six months, a rally largely driven by the company’s expanding role in the artificial intelligence sector.

ORCL one-month stock price chart. Source: Finbold
Now, analysis by charting platform TrendSpider suggests Oracle may be primed for another major rally toward $1,000, if historical patterns repeat. 

Orcale stock price analysis chart. Source: TrendSpider
The October 5 post on X used a monthly logarithmic chart comparing Oracle’s current price action to its 2000 Dot-com surge, when the stock soared before a sharp correction and long consolidation.

In the current setup, the highlighted 2025 zone mirrors the same sharp upward trajectory that preceded Oracle’s last parabolic move. If the historical fractal plays out proportionally, the projection suggests Oracle could extend its multi-year uptrend toward the $1,000 and $1,031 range.

Oracle stock fundamentals 
While the analysis doesn’t guarantee future gains, Oracle’s strong fundamentals could sustain the rally. For instance, the company’s latest quarterly report showed a 359% year-over-year surge in remaining performance obligations to about $455 billion, reflecting a robust cloud and AI service backlog and strong revenue visibility.

Another key catalyst is a new cloud deal expected to generate roughly $30 billion in annual revenue, reportedly linked to AI infrastructure clients such as OpenAI.

 Oracle’s participation in the Stargate project,  a multibillion-dollar AI data center initiative co-developed with OpenAI and SoftBank,  further strengthens its enterprise AI positioning.

To support this growth, Oracle has raised its capital expenditure target to $35 billion, plans to open 37 new data centers, and issued $18 billion in bonds, aligning with Big Tech’s accelerated AI buildout trend.

Leadership changes have also boosted investor confidence. To this end, ORCL shares surged in reaction in September 2025, when Clay Magouyrk and Mike Sicilia were appointed co-CEOs, replacing Safra Catz. 

Featured image via Shutterstock

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.